Biohaven Receives Favorable Ruling in the Trade Secret Misappropriation Lawsuit

05:23 PM EDT, 08/25/2026 (MT Newswires) -- Biohaven (BHVN) said late Tuesday that the US District Court for the District of Delaware ruled in favor of the company related to a trade secret misappropriation and breach of contract litigation against Avilar Therapeutics and RA Capital Management. The judgment, which confirmed that RA Capital and Avilar Therapeutics willfully misappropriated a trade secret developed at Yale University related to its "MODA" targeted protein degradation platform, formalized a $4 million award to the company and Yale, according to a statement. Biohaven did not immediately respond to a request for comment from MT Newswires.